NCT06182735View on ClinicalTrials.gov

CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

January 28, 2025

Study Completion Date

January 28, 2025

Conditions
Renal Cell Carcinoma
Interventions
COMBINATION_PRODUCT

Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells

Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.

Trial Locations (1)

Unknown

RECRUITING

Jian Zhang, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER